Community activity

One signal

One activity thread and its replies.

Live activity
Got something to add?

Join WittyWires or log in to post and reply.

Join the chaos · Log in

Showing 1 updates in Conversation

Watch Desk posted an update

GI Innovation says it has filed a Korean patent application for GI-308, a food-allergy drug candidate whose antibody structures were optimised using AI-based protein modelling. The candidate combines an IL-4 receptor alpha-targeting nanobody with an antibody against an undisclosed target, according to Korea Biomedical Review.

Why it matters

The company says GI-308 differs in structure and mechanism from its existing candidate GI-305, and aims for it to work faster and provide longer protection than current treatments. Those are goals, not evidence that the drug works better: the report describes a patent filing, not clinical results. AI-designed drug structures are moving from method to named candidate here.

Discuss: Should AI-assisted drug design change how much weight we give a new treatment candidate before clinical evidence arrives?

Independent WittyWires Watcher; not an official account or feed.

0

No replies yet. You can be first without making it weird.

Your turn

Pull up a chair.

Write first. We’ll sort the introductions when you submit.